Sarepta Therapeutics Appoints Michael Severino as New CEO Amidst Critical Strategic Crossroads and Post-Elevidys Challenges
admin Sarepta Therapeutics, a biopharmaceutical company at the forefront of genetic medicine for rare diseases, has...
drug development
FDA’s AI Ambitions Face Uncertainty Amid Leadership Departures and Shifting Strategy
The integration and evolution of artificial intelligence within the U.S. Food and Drug Administration (FDA)...
GSK Unveils Ambitious $2.5 Billion Restructuring Plan to Navigate Patent Cliff and Fuel Future Growth
London, UK – Pharmaceutical giant GSK has announced a comprehensive, multi-billion-dollar cost-cutting program designed to...
Claris Biotherapeutics Secures $118 Million Series B Funding and Fortifies Leadership for Late-Stage Eye Drug Development
Claris Biotherapeutics, a New Jersey-based biotechnology firm, has announced a significant milestone, successfully closing a...
FDA scientists question Capricor data; Legend CEO steps down
The biopharmaceutical industry experienced a dynamic week marked by significant corporate developments, regulatory challenges, and...
Argenx Acquires Forte Biosciences in Landmark $2.2 Billion Deal, Bolstering Immunology Pipeline with CD122-Targeting Antibody
Argenx, the Netherlands-based biopharmaceutical giant, announced on Monday, July 27, 2026, its definitive agreement to...
MapLight Therapeutics Shares Plummet by Two-Thirds After Phase 2 Schizophrenia Trial Results Spark Competitive Doubts Despite Positive Outcomes.
Brain drug developer MapLight Therapeutics witnessed a dramatic two-thirds erosion of its market value on...
Global Biotech Sector Rebounds with Surging Deals and Strategic Shifts in 2026: Insights from DIA China and BIO International
The global biotechnology sector is experiencing a significant resurgence of confidence in 2026, marked by...
Biopharma Industry Roiled by Obesity Drug Marketing Dispute, Groundbreaking Oncology Advances, and AI Biotech Leadership Shift
The biopharmaceutical landscape witnessed a flurry of significant developments this week, from a heated legal...
Sanofi Halts Amlitelimab Development, Marking Significant Setback in Blockbuster Ambitions and Raising Questions on OX40L Target
Sanofi, the global pharmaceutical giant, has officially ceased further development and pursuit of regulatory approval...
